DE60123399D1 - Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen - Google Patents

Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen

Info

Publication number
DE60123399D1
DE60123399D1 DE60123399T DE60123399T DE60123399D1 DE 60123399 D1 DE60123399 D1 DE 60123399D1 DE 60123399 T DE60123399 T DE 60123399T DE 60123399 T DE60123399 T DE 60123399T DE 60123399 D1 DE60123399 D1 DE 60123399D1
Authority
DE
Germany
Prior art keywords
trka
turn peptidomimetic
beta
extracellular domain
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123399T
Other languages
English (en)
Other versions
DE60123399T2 (de
Inventor
Uri Saragovi
Kevin Burgess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Texas A&M University System
Original Assignee
McGill University
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University, Texas A&M University System filed Critical McGill University
Application granted granted Critical
Publication of DE60123399D1 publication Critical patent/DE60123399D1/de
Publication of DE60123399T2 publication Critical patent/DE60123399T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
DE60123399T 2000-01-18 2001-01-18 Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen Expired - Lifetime DE60123399T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17648200P 2000-01-18 2000-01-18
US176482P 2000-01-18
PCT/CA2001/000043 WO2001052843A1 (en) 2000-01-18 2001-01-18 β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS

Publications (2)

Publication Number Publication Date
DE60123399D1 true DE60123399D1 (de) 2006-11-09
DE60123399T2 DE60123399T2 (de) 2007-08-23

Family

ID=22644525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123399T Expired - Lifetime DE60123399T2 (de) 2000-01-18 2001-01-18 Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen

Country Status (9)

Country Link
US (1) US6881719B2 (de)
EP (1) EP1265605B1 (de)
AT (1) ATE340571T1 (de)
AU (1) AU2001228212A1 (de)
CA (1) CA2397670C (de)
DE (1) DE60123399T2 (de)
DK (1) DK1265605T3 (de)
ES (1) ES2273849T3 (de)
WO (1) WO2001052843A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923015B2 (en) 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
EP1575477B1 (de) 2001-05-25 2012-04-25 Cornell Research Foundation, Inc. HOCHAFFINER LIGAND FÜR p75 NEUROTROPHIN-REZEPTOR
AUPR604401A0 (en) * 2001-06-29 2001-07-26 University Of Wollongong, The Peptoid compounds
CA2511598C (en) 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7785829B2 (en) 2003-03-19 2010-08-31 Biogen Idec Ma, Inc. Nogo receptor binding protein
US7521420B2 (en) 2003-06-18 2009-04-21 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0512500A (pt) 2004-06-24 2008-03-11 Biogen Idec Inc tratamento ou condições envolvendo desmielinação
WO2006005740A2 (en) * 2004-07-14 2006-01-19 Janssen Pharmaceutica N.V. P75ntr screening assay for indentifying modulators of apoptosis
JP2008516979A (ja) * 2004-10-14 2008-05-22 リゲル ファーマシューティカルズ インコーポレーティッド Ｉｒｅｓ仲介性翻訳の複素環式阻害剤およびその使用法
EP2586445A1 (de) * 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Verfahren zur Ermöglichung des Überlebens von Nervenzellen mit Neurotrophin-Mimetika
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US8686045B2 (en) 2005-06-08 2014-04-01 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
US8642040B2 (en) 2006-07-24 2014-02-04 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
AU2011253937B2 (en) * 2006-12-05 2012-09-27 The Royal Institution For The Advancement Of Learning/ Mcgill University Methods of use of TRK receptor modulators
AU2007327990A1 (en) * 2006-12-05 2008-06-12 The Royal Institution For The Advancement Of Learning/ Mcgill University Methods of use of TRK receptor modulators
AU2008311251B9 (en) * 2007-10-11 2014-04-17 Biogen Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
CN102046166B (zh) 2008-04-04 2012-10-17 米梅托根药物公司 用于治疗干眼症的β-转角模拟肽环状化合物
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
AU2010217889B2 (en) 2009-02-27 2014-12-18 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
ES2712752T3 (es) 2009-11-12 2019-05-14 Pharmatrophix Inc Formas cristalinas de compuestos miméticos de neurotrofina y sus sales
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2013191926A1 (en) 2012-06-22 2013-12-27 Mimetogen Pharmaceuticals, Inc. Synthesis of beta-turn peptidomimetic cyclic compounds
AU2014228017B2 (en) 2013-03-15 2018-08-30 Pharmatrophix, Inc. Non-peptide BDNF Neurotrophin mimetics
WO2014144342A1 (en) 2013-03-15 2014-09-18 Pharmatrophix, Inc. Non-peptide bdnf neurotrophin mimetics
US9657059B2 (en) 2013-09-09 2017-05-23 Canimguide Therapeutics Ab Immune system modulators
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
WO2017005902A1 (en) 2015-07-09 2017-01-12 Mimetogen Pharmaceuticals, Inc. Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
WO2022009992A1 (ja) * 2020-07-10 2022-01-13 国立大学法人東京大学 環状ペプチド、ペプチド複合体、並びに、当該環状ペプチド及び／又は当該ペプチド複合体を含む医薬組成物
WO2024031084A2 (en) * 2022-08-05 2024-02-08 The Texas A&M University System Compositions and methods for dye-bound cyclized peptides for medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034224A (en) * 1989-05-30 1991-07-23 American Cyanamid Company Method and composition for treating protozoal infections
EP0563256B1 (de) * 1990-12-21 1995-06-28 MicroCarb Inc. Verwendung von Wirtszellphospholipiden zur Hemmung bakterieller Besiedlung
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses

Also Published As

Publication number Publication date
AU2001228212A1 (en) 2001-07-31
DE60123399T2 (de) 2007-08-23
DK1265605T3 (da) 2007-02-12
EP1265605A1 (de) 2002-12-18
US6881719B2 (en) 2005-04-19
CA2397670A1 (en) 2001-07-26
WO2001052843A1 (en) 2001-07-26
EP1265605B1 (de) 2006-09-27
US20030211982A1 (en) 2003-11-13
CA2397670C (en) 2010-06-08
ATE340571T1 (de) 2006-10-15
ES2273849T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
DE60123399D1 (de) Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen
Contreras et al. Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone.
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
ATE381560T1 (de) Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind
DE69942753D1 (de) Peptidantagonist von Zonulin und dessen Verwendung
DE69638074D1 (de) Imidazolderivate als histamin-h3-modulatoren
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
IT1306704B1 (it) Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
TR200002015T2 (tr) Protein tirosin kinaz inhibitörleri olarak bisiklik heteroaromatik bileşikler.
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
WO1997024436A3 (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
ATE211737T1 (de) Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten
DE50006420D1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
ATE227276T1 (de) Neue pyrimidinderivate
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
PT1042320E (pt) Novos compostos que sao antagonistas de receptores duplos de ourinoceptores p2 e de proteina g 7-transmembranar
Mathews et al. In vivo characterization of (−)(−) MCL-144 and (+)(−) MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties
Kruk et al. Effects of the histamine H3 receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice
Zaitseva et al. Prospects of a search for kappa-opioid receptor agonists with analgesic activity
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
Kaufman et al. Characterization of ligand binding to immobilized biotinylated extracellular domains of three growth factor receptors
Goldman et al. Pharmacological validation of the two-dopamine-receptor hypothesis
DE69833866D1 (de) Pharmazeutische zusammensetzungen mit neurotrophischen biologischen aktivität

Legal Events

Date Code Title Description
8364 No opposition during term of opposition